


Laboratory of
ecosystem management

Dealing with toxic impacts in life cycle assessment






ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE


Olivier Jolliet
with contributions from David Pennington,
Pierre Crettaz, Geneviève Perrenoud and
Simon-Pierre Keller



**Industrial ecology - Life Cycle Systems,
Institute of Environmental Science and Technology,
Ecole Polytechnique Fédérale de Lausanne (EPFL),
CH-1015 Lausanne, Switzerland.**
olivier.jolliet@epfl.ch, <http://gecos.epfl.ch/lcsystems>

Portland dose-response workshop, 14 November 2004







 **ILSII panel 95: Limitations of RfD for an application to LCIA** 


Burke et al., 1996 (ILSII panel) recommended to use the NOAEL or response doses rather than RfD,

since the comparison of toxic releases based on their RfD can be biased, because:

- The UFs applied to derive the RfD are conservative.
- The response level associated with the No Observable Adverse Effect Level (NOAEL) can change.
- The RfD is dependent on the experimental design.

Appendix B: Dose Response Workshop


O. Jolliet Presentation



Laboratory of
ecosystem management


ILSI Panel

Severity: Burke et al., 1996



ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE

Subcategory 1 (Irreversible/life-shortening effects)	Subcategory 2 (Maybe reversible / maybe life-shortening)	Subcategory 3 (Generally reversible/generally not life-shortening)
Cancer Reproductive effects Teratogenic effects Acute fatal or acute severe and irreversible effects (i.e. fatal poisoning) Mutagenicity	Immunotoxicity Neurotoxicity Kidney damage Liver damage Heart disease Pulmonary (i.e. asthma)	Irritation Sensitization Reversible acute organ effects (i.e. GI inflammation)




Laboratory of
ecosystem management

Dose - response / potency


SETAC-EU WGIA2

(working group on impact assessment)



ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE


Type of indicator	Key Advantages	Key Issues	LCIA application
Regulatory potency measures, ADIs, RFDs, RFCs	Widely adopted risk assessment	Inconsistent conservatism, adverse risk rather than low-dose risk	Hertwich Huijbregts Goedkoop and Spriensma, partly Hauschild et al.
Slope factors based on benchmark doses, such as ED_{10}	Introduced to provide a consistent basis for low-dose risk response carcinogens and non-carcinogens	Not widely adopted yet while implicit in most measures for non-carcinogenic effects	(Crettaz et al., 2001a, b) 1000 substances
Acute toxicity data, such as LD_{50} s and LC_{50} s	Widely available data.	Relative acute to chronic importance is unlikely to be consistent across chemical emissions.	Partly used in (Hauschild et al., 1997). Extrapolations acute to chronic data are widely adopted.



Laboratory of
ecosystem management


Severity based indicators

SETAC-EU WGIA2



ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE


Type of indicators	Key Advantages	Key Issues	LCIA application
Qualitative indicators			
ILSI classification: Health endpoints allocated to 3 categories (Burke et al., 1996)	Somewhat homogeneous group of health effects with different levels of severity.	3 categories allows rough severity ranking only. Weighting requires value judgement.	Demonstrated by Owens (2000) and adapted by Crettaz et al. (2001b)
Quantitative indicators			
Disability Adjusted Life Years (DALY), based on (Murray and Lopez, 1996), supported by WHO, World Bank	Allows aggregation of mortality and morbidity on a single cardinal scale.	No final consensus on weighting factors for different health effects. DALY not always possible	(Hofstetter), Eco- indicator '99 (Goedkopp and Spriensma (Crettaz et al. 2001a, b) present data for over 1000 chemicals.
Quality Adjusted Life Years (QALY) (e.g. Rosser, 1987)	(similar to DALY)	(similar to DALY)	not currently used in LCIA but in RA
Years Of Life Lost (YOLL)	aggregation of different mortality effects	Giving the same value to any life year: a value choice not cover non-fatal effects.	key indicator in ExternE-type applications (European Commission, 1999)



Laboratory of
ecosystem management

Human toxicity recommendations

A stepwise procedure (SETAC-EU WGIA2)



ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE


1. Toxicological potency indicators such as ED10 as a minimum default

- While methods in their infancy, it is encouraged to take into account relative severity,

--> 2. YOLL 3. DALY/QALY

Key tasks:


- Lack of toxicity data**
- Population density**
- Aggregation linked to severity authorised by international body**



Points to be addressed





- How to derive dose-response information for a large number of chemicals (eventually screening and advanced approaches) ?
- Relevance: How to relate the animal endpoint to human endpoints and eventually YLL, YLD ?
- How to make endpoints comparable, using e.g. DALY's ?







Points to be raised







- Extrapolations chemical with acute, QSAR: shows that restricted !!
- Severity: as soon as impact scores are added, a weighting is performed with equal severity. If all endpoints are kept separate → OK
- Interesting to come to DALY because: upper limit, put into perspective to observed damages
- Always come back to initial goal of comparison → kg equ substance to communicate
- The way it can be used in practice: BMW



















Laboratory of
ecosystem management


Compatibility between approaches






ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE



Unit risks versus epidemiologic approaches !

Impacts of particles:








 **Non carcinogens** 


Severity of the endpoints

DALYp: a simpler weighting is used

1	2	3
Irreversible/ life-shortening effects	May be irreversible/ life-shortening effects	Reversible / not life-shortening effects
Cancer	Immunotoxicity	Irritation
Mutagenicity	Neurotoxicity (*)	Sensitization
Teratogenic effects	Kidney damage	
Reproductive effects	Liver damage	
	Pulmonary disease	
	Heart disease	
100	10	1 [Burke et al, 1996]
6 DALY/pers	0.6 DALY/pers	0.06 DALY/pers




Cancers severity




Type of Cancer	W [-]	Disability		L [yr. lost]	Death		Disability + Death DALY _p = YLD _p + YLL _p [yr. lost/inc.]
		D [yr. lost/inc.]	YLD _p = W · D [yr lost/inc.]		N [inc.]	YLL _p = L/N [yr. lost/inc.]	
Mouth and oropharynx	0.145	4.3	0.62	3.2E+06	1.1E+06	2.9	3.5
Oesophagus	0.217	1.7	0.37	3.4E+06	3.8E+05	8.9	9.3
Stomach	0.217	2.9	0.63	7.0E+06	1.1E+06	6.5	7.2
Colon and rectum	0.217	3.7	0.80	3.9E+06	9.9E+05	3.9	4.7
Liver	0.239	1.6	0.38	6.3E+06	5.4E+05	11.6	12.0
Pancreas	0.301	1.2	0.37	1.5E+06	1.9E+05	7.9	8.3
Trachea, bronchus, lung	0.146	1.8	0.26	8.3E+06	1.1E+06	7.9	8.2
Melanoma	0.045	4.2	0.19	5.1E+05	1.7E+05	3.1	3.2
Breast	0.069	4.2	0.29	3.8E+06	1.1E+06	3.6	3.9
Cervix uteri	0.066	3.8	0.25	2.7E+06	4.5E+05	6.0	6.2
Corpus uteri	0.066	4.5	0.30	5.8E+05	3.1E+05	1.9	2.2
Ovary	0.081	3.4	0.28	1.3E+06	2.0E+05	6.4	6.7
Prostate	0.113	4.2	0.47	1.1E+06	6.8E+05	1.6	2.1
Bladder	0.085	4.2	0.36	9.8E+05	4.6E+05	2.1	2.5
Lymphomas and myeloma	0.089	3.5	0.31	3.0E+06	4.2E+05	7.2	7.5
Leukemia	0.112	3.1	0.35	4.4E+06	3.1E+05	14.3	14.6
Other cancers*	0.809	n.a.		1.3E+07	1.0E+06	13.0	13.0
Average							6.7

**Due to difficulty to determine human endpoint,
taken the average for all cancers**




Severity




Main challenges:

- Dose-response for animal → human endpoints
- No severity = (Implicit) weighting in LCA,
when summing up accross substances
assume equal severity !! Not ISO compatible
- Report death, N°cases, YLL, YLD separately
- Disability weight optionals, new approaches to
establish them



Relationship animal endpoint - human




Alternatives


- Stay at separate endpoints for animals (Owens)
- Endpoint animals = endpoint humans ? No !
- Start from human evidences and link it back to or use animal dose-response.

a) If similar endpoints human-animals = lower uncertainty

b) If different endpoints human-animals = high uncertainty in dose-response



Example carbon tetrachloride




Strong humans evidences	YLL/incidence years	Duration years	Disability weight	YLD	DALY
Cirrhosis	17	7.8	0.33	2.6	19.6
Hepatitis	2.14	0.17	0.20	0.04	2.18



Some Comments on LCIA for Noncancer Effects


Lorenz Rhomberg, Ph.D.
Gradient Corporation
Cambridge, MA
lrhomberg@gradientcorp.com


$$IMPACT = \left[\frac{Pop'n.}{Exposed} \right] \times \left[\frac{Avg.}{Exposure} \right] \times \left[\frac{Risk\ per}{person - unit\ Exposure} \right]$$

$$\frac{IMPACT}{unit\ emission} = \left[\frac{[Pop'n. Exposed] \times [Avg. Exposure]}{unit\ emission} \right] \times [Risk\ per\ person - unit\ Exposure]$$

Risk must be a linear function of Exposure
(in the range of interest)

Appendix B: Dose Response Workshop L. Rhomberg Presentation




For Noncancer Effects

- Threshold effects; nonlinear dose-response
- Traditional approach focuses on identifying a dose-rate likely to be "safe" (and not on dose-response)

LCIA Needs for Assessing Noncancer Effects


1. An approach to nonlinear dose-response in humans
2. Estimates of the numbers of people exposed at different levels



Source: SJS Baird *et al.*, SRA, 2000

Appendix B: Dose Response Workshop

L. Rhomberg Presentation




The challenge for exposure analysis:
to express the population distribution
of exposure
(per unit of emissions, without specific times
and places).

Appendix B: Dose Response Workshop

L. Rhomberg Presentation

Air Emissions

632 11 CHARACTERISTIC TIME, CHARACTERISTIC TRAVEL DISTANCE



$$\text{Population-based potential dose} = \iint P(x, y) \times \text{ADD}(x, y) dx dy \quad (11.8)$$

where P is the population density (persons/m²) and ADD is the dose per person (mg/kg-d). In this equation, both the dose per person and the population density can vary spatially.





Figure 11.8 Cumulative percentile distribution of population-based potential dose for each calculation method for TCDD (a chemical with a long characteristic travel distance, CTD).

Source: Bennett, DH; McKone, TE; Kastenber, WE. 2002. Characteristic time, characteristic travel distance, and population-based potential dose in a multimedia environment: A case study. Human and Ecological Risk Assessment: Theory and Practice (Ed.: Paustenbach, DJ). John Wiley & Sons, Inc.


Europe Population Density, 1995



Source: <http://sedac.ciesin.columbia.edu/plue/gpw/europe.html>


Appendix B: Dose Response Workshop L. Rhomberg Presentation

Surface Water Emissions



Source: www.great-er.org

Dietary Exposures



Source: The Lifeline Group

Appendix B: Dose Response Workshop

L. Rhomberg Presentation

